Abiopharma

GALERA THERAPEUTICS, INC. (GRTX)

Symbol	GRTX
Name	GALERA THERAPEUTICS, INC.
Sector	UNDEFINED
Region	North America
Industry	-
Address	19355 United States PA 101 Lindenwood Drive Suite 225
Telephone	(610) 725-1500
Fax	—
Email	—
Website	http://www.galeratx.com/
Incorporation	US
Incorporated On	2012
Employees	—
Fiscal Year	12/31
Public Since	—
Exchanges	OTC;NASDAQ
Auditor	KPMG LLP - New York, New York, (USA);
Audit Status	AUDITED
Reporting Status	U.S. Reporting: SEC Reporting
CIK	0001563577
Description	Galera develops small molecules targeting cancer vulnerabilities in tumor cells, in immune cells and in the tumor microenvironment, including superoxide dismutase (SOD) mimetics and nitric oxide synthase (NOS) inhibitors. Excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galeras SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advanced breast cancer. Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion. Galeras tilarginine (L-NMMA) inhibits NO production, showing promise in combination with taxane chemotherapy for resistant breast cancer. It is undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer. Additional info from OTC: Galera develops small molecules targeting cancer vulnerabilities in tumor cells, in immune cells and in the tumor microenvironment, including superoxide dismutase (SOD) mimetics and nitric oxide synthase (NOS) inhibitors. Excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galeras SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advanced breast cancer. Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion. Galeras tilarginine (L-NMMA) inhibits NO production, showing promise in combination with taxane chemotherapy for resistant breast cancer. It is undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer.

2026-04-14 18:14

GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

2026-04-14 18:08

Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

2026-04-14 12:54

Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

2026-02-18 11:01

(99% Neutral) Galera Therapeutics, Inc. (GRTX) Announces Executive Changes

2026-02-12 21:06

(99% Neutral) Galera Therapeutics, Inc. (GRTX) Announces Executive Changes

2025-11-24 21:42

Sorensen Mel 🔴 sold 70.0K shares of Galera Therapeutics, Inc. (GRTX) at $0.02 Transaction Date: Nov 20, 2025 | Filing ID: 004171

2025-11-20 18:27

📋 Sorensen Mel (Officer) plans to sell 70K shares of Galera Therapeutics, Inc. (at $0.02 each, total $1K) Filed: Nov 20, 2025 | ID: 000433

2025-10-27 11:30

(99% Neutral) GALERA THERAPEUTICS, INC. (GRTX) Announces Business Combination

2025-10-22 11:00

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million

2025-10-21 20:05

(99% Neutral) GALERA THERAPEUTICS, INC. (GRTX) Announces Business Combination